CN1522727A - Prostate hyperplasia pharmaceutical and method for making same - Google Patents
Prostate hyperplasia pharmaceutical and method for making same Download PDFInfo
- Publication number
- CN1522727A CN1522727A CNA031175325A CN03117532A CN1522727A CN 1522727 A CN1522727 A CN 1522727A CN A031175325 A CNA031175325 A CN A031175325A CN 03117532 A CN03117532 A CN 03117532A CN 1522727 A CN1522727 A CN 1522727A
- Authority
- CN
- China
- Prior art keywords
- gryllotalpa
- medicine
- pollen tyjphae
- prescription
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002307 prostate Anatomy 0.000 title abstract description 24
- 238000000034 method Methods 0.000 title description 10
- 206010020718 hyperplasia Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 10
- 241001243091 Gryllotalpa Species 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 241000411851 herbal medicine Species 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 4
- 241000241125 Gryllotalpa gryllotalpa Species 0.000 abstract 1
- 210000004907 gland Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 206010025482 malaise Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019890 Amylum Nutrition 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 241001446509 Psoralea Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940072254 proscar Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 229960001909 terazosin hydrochloride Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a Chinese medicine in treating hyperplasia of prostate. It is a preparation consisted of mole cricket or its extract component, and add other Chinese medicinal materials ase as auxiliary medicine. Said invention not only can reduce the volume of prostate and relieve the patient's condition, but also can inhibit alpha-receptor so as to quickly relieve clinical symptoms of the patient with hyperplasia of prostate. Said invention also provides its preparation process.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of prostatic hyperplasia.Be the Chinese patent medicine that primary raw material is prepared from Gryllotalpa or Gryllotalpa and Pollen Tyjphae specifically.The invention still further relates to manufacturing method for above mentioned medicine.
Background technology
Hyperplasia of prostate (BPH) is the common disease of elderly men, and its sickness rate increases with the increase at age, reports according to documents and materials, 50～60 years old sickness rate is 50%, 60～70 years old sickness rate is that 60%, 70～80 years old sickness rate is that sickness rate more than 80%, 90 years old is 100%.According to reports, China more than 60 years old elderly men population reached 1.5 hundred million people, calculate by 60% sickness rate, add and suffered from BPH person in the past in 60 years old, China has 100,000,000 people to suffer from BPH approximately at present.
BPH can cause that controlled micturition difficulty, difficulty in micturition, urine urgency-frequency, nocturia increase etc., further develops complication such as can causing serious urinary tract infection, vesical calculus, hematuria, urine retention, kidney merit decline, inguinal hernia, has a strong impact on patient's quality of life.
The treatment means of BPH is a lot, but the various means of existing both at home and abroad treatment BPH run into following thorny problem:
1. operative treatment has certain traumaticly, and complication is many, and the old people is poor to the toleration of operation and anesthesia.
2. relief of symptoms in a short time such as naturopathy such as microwave, radio frequency, high-energy focusing also has complication such as urethral stricture.
3. dwindle the medicine such as the finasteride (proscar) of prostate volume, prostate volume is dwindled, but price more expensive (9 yuan/day), and onset slow (onset in March); And can cause side effect such as hyposexuality, sexual impotence.
4. alleviate the medicine example hydrochloric acid Tamsulosin (breathing out happy) of BPH patient's symptom, price is 8 yuan/day, can comparatively fast alleviate the clinical symptoms of BPH controlled micturition difficulty, but prostate volume is dwindled and delays BPH patient's disease progression; Can cause as headache, orthostatic hypotension even make us unacceptable side-effects.
Though research at present has the Chinese patent medicine of some treatment hyperplasia of prostates, but still can not satisfy patient's needs, and its prescription composition is all complicated, flavour of a drug are more, and price is higher, unsatisfactory curative effect.
Summary of the invention
The object of the present invention is to provide the Chinese medicine and the corresponding preparations thereof for the treatment of the prostatic hyperplasia determined curative effect simply.Its characteristics have: can comparatively fast alleviate BPH patient's clinical symptoms, can dwindle prostate volume again, and low price, have no side effect.
Solution of the present invention is based on the pathogenetic understanding of motherland's medical science to BPH, according to oneself clinical experience for many years, determines the effective Chinese medicine of a series of treatment BPH earlier from numerous Chinese medicines, verify repeatedly through clinical again, and the single medicinal material that screens.Can this single medicinal material be the basis also, add other Chinese medicine and form compound Chinese medicinal preparation.Can comparatively fast alleviate BPH controlled micturition difficulty symptom and remove its misery, can dwindle prostate volume again and delay its disease progression, and low price, have no side effect.
Medicine of the present invention is formed and is mainly Gryllotalpa: perhaps be Gryllotalpa and Pollen Tyjphae (its weight proportion is 1～100: 0～99, is preferably 40～60: 40～60, the best is 50: 50).
Medicine composition of the present invention can also contain one or more in the Chinese medicines such as Cortex Cinnamomi, Herba Leonuri, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Herba Lycopi, Spina Gleditsiae, Fructus Psoraleae.
Medicine of the present invention can be the medicine of said dosage form on any pharmaceutics.
The preparation of this medicine can prepare by the conventional method on the various medicaments, as:
Directly Gryllotalpa is ground into fine powder, perhaps Gryllotalpa is used solvent extraction, reclaim solvent, remove degrease, drying gets Gryllotalpa extract, is made into the medicine of required dosage form.
Pollen Tyjphae etc. extract according to a conventional method with ethanol or water etc., then Gryllotalpa or Gryllotalpa extract are mixed evenly with each extracts such as Pollen Tyjphae, make the medicine of required dosage form.
The solvent that is used for extracting Gryllotalpa can be the mixed solvent of one or more compositions of water, methanol, ethanol, ethyl acetate, petroleum ether, acetone, chloroform, cyclohexane extraction or normal hexane etc.
In the above preparation process, if necessary, can add adjuvant commonly used in an amount of pharmaceutics, as starch, dextrin, microcrystalline cellulose, amylum pregelatinisatum, magnesium stearate, micropowder silica gel, sucrose, carboxymethyl starch sodium etc.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
(1) symptoms such as the nocturia that causes of treatment BPH, dysuria, lower abdomen distension reduce international prostate gland symptoms scoring (I-PSS scoring), improve the quality of living.
(2) obviously improve the urine flow rate.
(3) obviously reduce residual urine volume.
(4) have no side effect.
(5) stable curative effect.
For showing clinical effectiveness of the present invention, with reference to " new Chinese medicine clinical research guideline " (1997), select more than 50 years old, be diagnosed as patient's 30 examples of prostatic hyperplasia, through the objective clinical observation of system.Minimum 51 years old of age, maximum 69 years old, average 61.53 ± 6.48 years old.The course of disease is the shortest 4 months, and is the longest 280 months, average 58.10 ± 42.35 months.6 examples that the state of an illness is slight (20%), moderate 13 examples (43.33%), severe 11 examples (36.67%).One month observation period.Instructions of taking: 10g/ day, divide 3 times oral.Respectively at taking medicine preceding and taking medicine the back observation:
(1) safety indexes: blood pressure, pulse, blood, urine, excrement three big routines and electrocardiogram, liver, kidney brake are checked
(2) health giving quality index:
(a) urine flow rate inspection: Qmax, AFR detect.
(b) residual urine volume is measured: adopt through abdomen B ultrasonic method.
(c) prostate volume detects: adopt per rectum B ultrasonic method.
(3) untoward reaction is observed
Comprise that gastrointestinal reaction, nervous system abnormality, skin and muscle are unusual etc.
Every index changes shown in table 1～4 before and after the treatment
International prostate gland symptoms scoring of table 1 (I-PSS) and quality of life index (QOL) change
I-PSS (branch) QOL (branch)
N
After treating before treating after treating before treating
30 23.4±6.2 8.9±6.3
*** 3.8±0.8 2.6±0.8
***
Annotate:
*Represent self cross-reference p＞0.05,
*Expression and preceding relatively p＜0.05 of treatment,
* *Compare p＜0.01 (down together) before expression and the treatment.
Table 2 Qmax (MFR), AFR (AFR) are relatively
MFR(ml/s) AFR(ml/s)
N
After treating before treating after treating before treating
30 9.3±2.8 15.2±3.7
*** 5.4±2.2 9.5±2.3
***
Annotate: the p value representation is the same.
Table 3 residual urine volume (PVR) relatively
After treating before N treats
30 56.0±21.5 29.8±14.2
***
Annotate: the p value representation is the same.
Table 4 prostate volume (ml) relatively
After treating before N treats
30 35.5±11.5 28.2±9.2
**
Annotate: the p value representation is the same.
Do not see obvious adverse reaction in the drug administration process, electrocardiogram before and after taking medicine, liver, renal function, blood, routine urinalysis do not have significant change.
For further checking the present invention dwindles the effect of prostate volume, adopt SD rat castration after subcutaneous injection testosterone propionate method duplicate the BPH model, with 5 times, 10 times, 20 times gastric infusion January that are equivalent to clinical adult's consumption, and establish the proscar matched group.Behind last administration 24h, behind the title rat body weight,, extract prostate through the femoral artery sacrificed by exsanguination.Claim rat prostate weight with electronic balance, and calculate prostate index (weight of prostate/rat body weight * 100%); The water method of substitution is measured prostate volume, unit/ml.Get the same area prostata tissue, liquid-solid fixed 48 hours of FAA, dehydration of alcohol, waxdip step by step, paraffin embedding, section, thickness 4 μ m do conventional H E dyeing, the variation of observation HE staining section prostata tissue structure under 4 * 10 mirrors.
The rat prostate volume is respectively organized in test and weight sees Table 5
Table 5 is respectively organized relatively (x ± SD) of rat prostate weight, volume, index
Group n rat body weight (g) weight of prostate (g) prostate volume (ml) prostate index (%)
Normal group 8 304.00 ± 28.07 0.84 ± 0.25 0.73 ± 0.17 0.27 ± 0.07
Model group 8 323.75 ± 26.69 1.57 ± 0.28
△ △1.39 ± 0.25
△ △0.49 ± 0.08
△ △
Heavy dose of group 8 306.86 ± 31.16 1.02 ± 0.28
※ ※0.88 ± 0.18
※ ※0.34 ± 0.12
※ ※
Middle dosage group 8 290.63 ± 34.48 0.91 ± 0.19
※ ※0.79 ± 0.16
※ ※0.32 ± 0.06
※ ※
Small dose group 8 291.25 ± 19.59 1.03 ± 0.23
※ ※0.89 ± 0.21
※ ※0.35 ± 0.07
※ ※
Proscar group 8 312.63 ± 33.75 0.95 ± 0.27
※ ※0.82 ± 0.20
※ ※0.33 ± 0.13
※ ※
Annotate: △ represents to compare with the normal control group, P＜0.05, and △ △ represents to compare P＜0.01 with the normal control group;
※ represents to compare with the model group group, P＜0.05, and ※ ※ represents to compare P＜0.01 with the model group group.
The result shows: the model group prostate volume increases, and the present invention can dwindle BPH rat prostate volume.
The prostata tissue constructed observation is respectively organized in test: normal control group body of gland is arranged clear, between body of gland visible significantly between matter, lumen of gland does not have expansion, glandular epithelium monolayer column, as seen a little basal cell and obvious basement membrane. model group body of gland dense arrangement, lumen of gland become big, the expansion of part body of gland, the luminal sectetion thing increases, and epithelial cell is the monolayer column, the glandular epithelium thickening, the subregion is false multiple layer, it is prominent to intracavity that the part body of gland is mamillary, visible more basal cell, the little vasodilation hyperemia of a matter; Between the matter smooth muscle increase.The above various changes of each dosage group of the present invention and proscar group all have improvement in various degree.
For clearly inventing the mechanism of alleviating BPH patient's clinical symptoms, designed the test of " influence that the stripped trigone of bladder flesh of the inductive rabbit of norepinephrine (NE) shrinks ", setting up distilled water simultaneously is blank, the positive matched group of terazosin hydrochloride.Result of the test is as shown in table 6.
The influence that the rabbit trigone of bladder flesh that each group of table 6 test is brought out NE shrinks (x ± S)
Group sample number (N) suppression ratio (%)
Of the present invention group 10 21.4730 ± 9.1559
△ △
Hytrin 10 47.9650 ± 11.1554
△ △
Distilled water 10 0.5510 ± 8.7201
△ △ represents to compare P＜0.01 with the distilled water group.
The result shows, the present invention can suppress the rabbit trigone of bladder flesh contraction that NE brings out, the receptor that distributes because of trigone of bladder flesh, neck of bladder, capsula prostatica is alpha-receptor, illustrates that this invention can comparatively fast alleviate the clinical symptoms of BPH controlled micturition difficulty by suppressing alpha-receptor.
The specific embodiment
The invention will be further described below in conjunction with embodiment.
Medicine of the present invention can be made up of and different proportion relations multiple heterogeneity, as (consumption is weight percentage):
(1) Gryllotalpa 20 Fructus Psoraleaes 15 Herba Leonuris 20 Cortex Cinnamomis 10 Radix Paeoniae Rubra 10 Radix Salviae Miltiorrhizaes 15 Herba Lycopi 10
(2) Gryllotalpa 30 Pollen Tyjphae 20 Herba Leonuris 20 Herba Lycopi 20 Cortex Cinnamomis 10
(3) Gryllotalpa 30 Pollen Tyjphae 20 Radix Paeoniae Rubra 20 Radix Salviae Miltiorrhizaes 20 Spina Gleditsiae 10
(4) Gryllotalpa 50 Pollen Tyjphae 50
(5) Gryllotalpa 60 Pollen Tyjphae 40
(6) Gryllotalpa 70 Pollen Tyjphae 30
(7) Gryllotalpa 65 Pollen Tyjphae 35
(8) Gryllotalpa 40 Pollen Tyjphae 60
(9) Gryllotalpa 30 Pollen Tyjphae 70
(10) Gryllotalpa 10 Pollen Tyjphae 90
(11) Gryllotalpa 90 Pollen Tyjphae 10
(12) Gryllotalpa 20 Pollen Tyjphae 80
(13) Gryllotalpa 80 Pollen Tyjphae 20
(14) Gryllotalpa 100
The preparation method of medicine of the present invention is an example with Gryllotalpa, Pollen Tyjphae (percentage by weight 50: 50), can be with reference to following method:
(1) directly Gryllotalpa is ground into fine powder; The Pollen Tyjphae alcohol reflux reclaims solvent, and drying gets the Pollen Tyjphae extract, then Gryllotalpa is mixed evenly with the Pollen Tyjphae extract, adds appropriate amount of starch, granulates, and is processed into granule.
(2) Gryllotalpa is used alcohol reflux, behind the recovery solvent that extract is freezing, to remove degrease, drying gets Gryllotalpa extract; Pollen Tyjphae is pressed the percolation method with ethanol and is extracted, and reclaims solvent, and drying gets the Pollen Tyjphae extract, then Gryllotalpa extract is mixed evenly with the Pollen Tyjphae extract, makes the medicine of required dosage form, adds an amount of microcrystalline cellulose, granulates, and is processed into tablet.
(3) Gryllotalpa is used ethyl acetate extraction, reclaim solvent, drying gets Gryllotalpa extract; The Pollen Tyjphae water is pressed decocting method and is extracted, and concentrates, and drying gets the Pollen Tyjphae extract, then Gryllotalpa extract is mixed evenly with the Pollen Tyjphae extract, makes the medicine of required dosage form.Add an amount of dextrin, granulate, be processed into capsule.
And for example, consist of Gryllotalpa 20, Fructus Psoraleae 15, Herba Leonuri 20, Cortex Cinnamomi 10, Radix Paeoniae Rubra 10, Radix Salviae Miltiorrhizae 15, Herba Lycopi's 10 tablet, its preparation method is:
Gryllotalpa is pressed the percolation method with ethanol extract, behind the recovery solvent that extract is freezing, to remove degrease, drying gets Gryllotalpa extract; Other each medicines with water boiling and extraction repeatedly filter, and merge each extracting solution, concentrate, and drying with the Gryllotalpa extract mix homogeneously, adds an amount of amylum pregelatinisatum, granulate, and tabletting, promptly.
Claims (10)
1. medicine for the treatment of prostatic hyperplasia, the composition that contains Gryllotalpa in it is characterized in that writing out a prescription or extract by Gryllotalpa.
2. according to the medicine of claim 1, it is characterized in that also containing Pollen Tyjphae in the prescription.
3. according to the medicine of claim 2, it is characterized in that writing out a prescription and form by Gryllotalpa and Pollen Tyjphae two herbal medicines.
4. according to the medicine of claim 3, weight (part) ratio range of Gryllotalpa and Pollen Tyjphae is in it is characterized in that writing out a prescription: Pollen Tyjphae 0～99%, Gryllotalpa 1～100%.
5. according to the medicine of claim 4, weight (part) ratio range of Gryllotalpa and Pollen Tyjphae is in it is characterized in that writing out a prescription: Pollen Tyjphae 40～60%, Gryllotalpa 40～60%.
6. according to the medicine of claim 4, weight (part) ratio range of Gryllotalpa and Pollen Tyjphae is in it is characterized in that writing out a prescription: Pollen Tyjphae 50%, Gryllotalpa 50%.
7. according to claim 1,2,3,4,5 or 6 described medicines, it is characterized in that said medicine is the medicine of said dosage form on any pharmaceutics.
8. the preparation method of the medicine of the described treatment prostatic hyperplasia of claim 7 is characterized in that directly Gryllotalpa being ground into fine powder, perhaps Gryllotalpa is used solvent extraction, reclaims solvent, removes degrease, and drying gets Gryllotalpa extract, makes the medicine of required dosage form again.
9. preparation method according to Claim 8, the solvent that it is characterized in that being used for extracting Gryllotalpa can be the mixed solvent of one or more compositions of water, methanol, ethanol, ethyl acetate, petroleum ether, acetone, chloroform, cyclohexane extraction or normal hexane.
10. preparation method according to Claim 8 is characterized in that Pollen Tyjphae etc. extracts according to a conventional method with ethanol or water etc., then each extract is mixed evenly, makes the medicine of required dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031175325A CN1259943C (en) | 2003-03-25 | 2003-03-25 | Prostate hyperplasia pharmaceutical and method for making same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031175325A CN1259943C (en) | 2003-03-25 | 2003-03-25 | Prostate hyperplasia pharmaceutical and method for making same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1522727A true CN1522727A (en) | 2004-08-25 |
| CN1259943C CN1259943C (en) | 2006-06-21 |
Family
ID=34284762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031175325A Expired - Fee Related CN1259943C (en) | 2003-03-25 | 2003-03-25 | Prostate hyperplasia pharmaceutical and method for making same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1259943C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939431B (en) * | 2005-09-30 | 2011-01-12 | 邵继春 | Medicine for treating prostatic accrementition |
| CN104667027A (en) * | 2015-03-31 | 2015-06-03 | 华梅 | Traditional Chinese medicine liquor for treating prostatic hyperplasia and preparation method of traditional Chinese medicine liquor |
| CN110772623A (en) * | 2019-12-18 | 2020-02-11 | 张吉方 | Traditional Chinese medicine for treating prostate |
-
2003
- 2003-03-25 CN CNB031175325A patent/CN1259943C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939431B (en) * | 2005-09-30 | 2011-01-12 | 邵继春 | Medicine for treating prostatic accrementition |
| CN104667027A (en) * | 2015-03-31 | 2015-06-03 | 华梅 | Traditional Chinese medicine liquor for treating prostatic hyperplasia and preparation method of traditional Chinese medicine liquor |
| CN110772623A (en) * | 2019-12-18 | 2020-02-11 | 张吉方 | Traditional Chinese medicine for treating prostate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1259943C (en) | 2006-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1843399A (en) | Medicine for treating benign prostate hyperplasia and its preparation process | |
| CN107951980B (en) | Application of hosta plantaginea flower and extract thereof in preparing medicine for treating chronic prostatitis | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1628768A (en) | Medicine for treating gout affection and its symptoms | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN1686458A (en) | Chinese medicinal composition, its preparation method and use | |
| CN1876038A (en) | A Chinese medicinal composition for treating stomach and abdomen pain and preparation method thereof | |
| CN1259943C (en) | Prostate hyperplasia pharmaceutical and method for making same | |
| CN1698858A (en) | A pharmaceutical composition for treating acute gout and its extraction method | |
| CN1067901C (en) | Drug for curing migraine and its preparing method | |
| CN1155380C (en) | Application of sophocarpidine oxide in preparing medicine to treat ulcerative colitis | |
| CN1989995A (en) | Medicine for treating benign prostate hyperplasia and its preparation process | |
| CN102940656B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN101480424B (en) | Medicine for treating prostatosis and method for preparing same | |
| CN1857492A (en) | Qingxie preparation and its preparing process | |
| CN102940655B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN102940674B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN1224397C (en) | Medicine for treating chronic nephritis and production process thereof | |
| CN1566108A (en) | Red clover total flavone high content extract, preparation and application in pharmaceutical combination thereof | |
| CN1218697C (en) | Pharmaceutical composition and dietary supplement for treating or improving arthritis | |
| CN1446554A (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1660329A (en) | Medication of possessing effect for reducing fat and treating fatty liver | |
| CN1246012C (en) | Medicine for treating endometriosis and its preparing process | |
| CN1824204A (en) | Medicinal composition for treating acute urarthritis and its preparation method | |
| CN101053624A (en) | Traditional Chinese medicinal for treating prostatic hyperplasia and chronic prostatitis and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060621 Termination date: 20160325 |